KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.

Austin Kulasekararaj, Robert Brodsky, Hubert Schrezenmeier, Morag Griffin, Alexander Röth, Caroline Piatek, Masayo Ogawa, Ji Yu, Ami S Patel, Yogesh Patel, Rosario Notaro, Kensuke Usuki, Alexander Kulagin, Sandra Gualandro, Wolfgang Füreder, Regis Peffault de Latour, Jeff Szer, Jong Wook Lee

Ann Hematol 104(1) 81-94

PMID39841198
PMCIDPMC11868214
DOI10.1007/s00277-025-06193-5
发表日期2025-01-22
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Ravulizumab is a second-generation complement component 5 (C5) inhibitor (C5i) approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) following positive results from two pivotal trials in patients with PNH originally naive to C5i treatment and eculizumab-experienced patients with PNH. In both trials, after the 26week primary evaluation period, all patients received ravulizumab for up to 6 years. To report ravulizumab treatment outcomes in patients with PNH originally naive to C5i treatment and eculizumab-experienced patients with PNH treated for up to 6 years. Originally C5i-naive (N = 244) and eculizumab-experienced (N = 191) patients with PNH continued ravulizumab treatment for up to 6 years. Major adverse vascular events (MAVEs; including thrombotic events [TEs]) and survival are reported, including a comparison of survival with untreated patients from the International PNH Registry. Laboratory parameters for intravascular hemolysis (IVH) are also described. For up to 6 years (1468.0 patient-years of exposure), ravulizumab provided durable control of terminal complement activity and IVH, resulting in a low incidence of MAVEs (including TEs) reported (MAVE rate: 0.7-1.4 per 100 patient-years) and, compared with untreated patients from the International PNH Registry, reduced the risk of mortality by five-fold. The few breakthrough IVH events reported (N = 122) were commonly associated with complement-amplifying conditions, and only two events (1.8%) were associated with suboptimal inhibition of C5 (i.e. serum free C5 ≥ 0.5 µg/mL). These results support the long-term use of ravulizumab as the first-line treatment of choice for patients with PNH. Trial registration details: NCT01374360; registered: October 29, 2004; NCT02946463; registered: October 27, 2016; NCT03056040; registered: June 05, 2017.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 2

Overall survival of the eculizumab-experienced group during ravulizumab treatment. Reference: Kulasekararaj et al. [ 40 ]. Period of eculizumab treatment experience was not included in this analysis. Mortality rate = 0.6 per 100 PYs; 98.4% survival rate. PNH, paroxysmal nocturnal hemoglobinuria; PY, patient-year

Overall_survival

Overall survival

Fig. 2 · Panel Overall_survival

complete 待 EXE 对齐 预期 1 条 已提取 1 条

Panel Overall_survival 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Disposition of patients included in the analyses. a Overall, 243 C5i-naive patients with ≥ 5% of PNH granulocyte population were eligible for comparative survival analysis. C5i, complement component 5 inhibitor; PNH, paroxysmal nocturnal hemoglobinuria
非 KM Figure
Fig. 3Adjusted survival analysis of ravulizumab-treated patient in the C5i-naive group and untreated patients with PNH. Reference: Kulasekararaj et al. [ 41 ]. © American Society of Hematology (2024). Reused with permission. Period of eculizumab treatment experience was not included in this analysis. Covariates included in the final adjusted model included patient transfusion history ( p = 0.05), age at PNH diagnosis and gender. C5i, complement component 5 inhibitor; CI, confidence interval; HR, hazard ratio; PNH, paroxysmal nocturnal hemoglobinuria
非 KM Figure
Fig. 4Mean (95% CI) LDH level over time for patients with PNH in ( a ) the C5i-naive group and ( b ) eculizumab-experienced group, by treatment sequence. References: (a) Kulasekararaj et al. [ 41 ]. © American Society of Hematology (2024). Reused with permission. (b) Kulasekararaj et al. [ 40 ]. Note. On both charts, the lower horizontal line indicates the ULN (246 U/L) and the upper horizontal line indicates 1.5 × ULN (369 U/L). Data points with sample sizes were less than 10 were excluded. CI, confidence interval; LDH, lactate dehydrogenase; PNH, paroxysmal nocturnal hemoglobinuria; ULN, upper limit of normal
非 KM Figure
Fig. 5Proportion of ravulizumab-treated patients avoiding transfusion in the ( a ) C5i-naive and ( b ) eculizumab-experienced groups. References: ( a ) Kulasekararaj et al. [ 41 ]. © American Society of Hematology (2024). Reused with permission. OLE, open-label extension; NA, not applicable; PNH, paroxysmal nocturnal hemoglobinuria
非 KM Figure